Ubiquitin-conjugating enzyme E2 C is a
protein that in humans is encoded by the UBE2Cgene.[5][6]
The modification of proteins with
ubiquitin is an important cellular mechanism for targeting abnormal or short-lived proteins for degradation. Ubiquitination involves at least three classes of
enzymes:
ubiquitin-activating enzymes, or E1s,
ubiquitin-conjugating enzymes, or E2s, and
ubiquitin-protein ligases, or E3s. This gene encodes a member of the E2 ubiquitin-conjugating enzyme family. This enzyme is required for the destruction of mitotic
cyclins and for
cell cycle progression. Multiple
alternatively spliced transcript variants have been found for this gene, but the full-length nature of some variants has not been defined.[6]
Fossey SC, Mychaleckyj JC, Pendleton JK, et al. (2001). "A high-resolution 6.0-megabase transcript map of the type 2 diabetes susceptibility region on human chromosome 20". Genomics. 76 (1–3): 45–57.
doi:
10.1006/geno.2001.6584.
PMID11549316.
Okamoto Y, Ozaki T, Miyazaki K, et al. (2003). "UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme". Cancer Res. 63 (14): 4167–73.
PMID12874022.
Takahashi Y, Ishii Y, Nishida Y, et al. (2006). "Detection of aberrations of ubiquitin-conjugating enzyme E2C gene (UBE2C) in advanced colon cancer with liver metastases by DNA microarray and two-color FISH". Cancer Genet. Cytogenet. 168 (1): 30–5.
doi:
10.1016/j.cancergencyto.2005.12.011.
PMID16772118.